{"gene":"ABCB1","run_date":"2026-04-28T17:12:36","timeline":{"discoveries":[{"year":1986,"finding":"The MDR1/ABCB1 gene encodes a 1280 amino acid membrane glycoprotein (P-glycoprotein) consisting of two homologous halves, each with six predicted transmembrane segments and a hydrophilic nucleotide-binding domain homologous to bacterial active transport proteins, consistent with a function as an energy-dependent efflux pump.","method":"cDNA sequencing, sequence analysis and homology comparison","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — foundational structural characterization, independently replicated, >1800 citations","pmids":["2876781","3768958"],"is_preprint":false},{"year":1986,"finding":"Overexpression of a single full-length mdr1 cDNA clone in drug-sensitive cells is sufficient to confer a complete multidrug-resistant phenotype, establishing that ABCB1 alone mediates multidrug resistance.","method":"cDNA transfection and drug resistance phenotyping","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct gain-of-function reconstitution, foundational study, >800 citations","pmids":["3022150"],"is_preprint":false},{"year":1988,"finding":"Spontaneous point mutations in the mdr1/ABCB1 gene during colchicine selection result in single amino acid changes in P-glycoprotein that alter the pattern of drug cross-resistance, demonstrating that substrate specificity is encoded within the P-glycoprotein sequence.","method":"cDNA sequencing of MDR cells, site-directed mutagenesis, transfection and drug resistance profiling","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional validation, >430 citations","pmids":["2897240"],"is_preprint":false},{"year":1989,"finding":"Gp170/P-glycoprotein functions as an ATP-dependent efflux pump for cytotoxic drugs (daunomycin) in rat liver canalicular membrane vesicles; transport requires ATP hydrolysis (non-hydrolyzable analogues are ineffective), is temperature-dependent, osmotically sensitive, saturable, and occurs only in inside-out vesicles, indicating unidirectional (cytoplasm-to-lumen) drug transport.","method":"Canalicular membrane vesicle transport assays, antibody-induced affinity density perturbation to separate inside-out from right-side-out vesicles, ATP analogue competition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted transport assay with rigorous controls, foundational mechanistic study","pmids":["2568355"],"is_preprint":false},{"year":1992,"finding":"Gp170/P-glycoprotein in rat small intestinal brush border membrane vesicles functions as an ATP-dependent efflux pump transporting substrates (daunomycin, rhodamine 123) unidirectionally from cytoplasm into the intestinal lumen; non-hydrolyzable ATP analogues are ineffective, demonstrating that ATP hydrolysis is required.","method":"Brush border membrane vesicle transport assays, everted intestinal sac transport experiments, P-gp inhibitor studies","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted transport assay, multiple orthogonal preparations","pmids":["1347031"],"is_preprint":false},{"year":1996,"finding":"MDR1 P-glycoprotein (ABCB1) functions as a broad-specificity lipid translocase, translocating short-chain analogs of various membrane lipids (phosphatidylcholine, sphingomyelin, glucosylceramide, phosphatidylethanolamine) to the apical membrane leaflet, while MDR3 P-gp specifically translocates phosphatidylcholine, establishing a lipid flippase activity for ABCB1.","method":"Stable transfection of LLC-PK1 epithelial cells, short-chain fluorescent lipid analogue translocation assays at 15°C (no vesicular secretion), MDR inhibitor and energy depletion controls","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — reconstituted cellular assay with rigorous controls, >750 citations","pmids":["8898203"],"is_preprint":false},{"year":2000,"finding":"A synonymous polymorphism in exon 26 (C3435T) of MDR1/ABCB1 significantly correlates with intestinal P-glycoprotein expression levels and function (digoxin absorption), demonstrating that this SNP or a linked variant modulates P-gp expression and substrate pharmacokinetics in vivo.","method":"Sequencing of MDR1 in volunteers, Western blot and quantitative immunohistology of duodenal P-gp, oral digoxin plasma level measurements","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (protein expression + in vivo pharmacokinetics), >1770 citations","pmids":["10716719"],"is_preprint":false},{"year":2001,"finding":"The MDR1*2 haplotype (C1236T/G2677T/C3435T) carrying Ser893 in exon 21 shows enhanced digoxin efflux in vitro and is associated with altered fexofenadine pharmacokinetics in vivo, identifying functionally variant ABCB1 alleles that differ in substrate transport efficiency.","method":"In vitro expression of MDR1 alleles with Ala893 vs Ser893, digoxin efflux assay, fexofenadine pharmacokinetics in human subjects stratified by genotype","journal":"Clinical pharmacology and therapeutics","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro functional assay plus in vivo pharmacokinetic validation, >830 citations","pmids":["11503014"],"is_preprint":false},{"year":2003,"finding":"Substrate recognition by P-glycoprotein occurs within the transmembrane domains at multiple overlapping binding sites; the protein hydrolyzes two ATPs per molecule of drug transported, with conformational changes in the transmembrane domains driven by ATP hydrolysis coupling energy to drug efflux.","method":"Biochemical assays, site-directed mutagenesis, photoaffinity labeling, ATPase activity measurements (review synthesizing multiple primary studies)","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 — synthesis of reconstitution, mutagenesis, and photoaffinity labeling data across multiple studies","pmids":["14576852"],"is_preprint":false},{"year":2005,"finding":"P-glycoprotein deficiency at the blood-brain barrier leads to significantly reduced clearance of Aβ40 and Aβ42 from the CNS and increased amyloid deposition in APP-transgenic mice, establishing a direct mechanistic role for ABCB1 in Aβ efflux transport across the BBB.","method":"Radiolabeled Aβ microinjection into CNS of Pgp-null vs WT mice, P-gp inhibitor administration in APP-transgenic mice, interstitial fluid Aβ measurement, APP-transgenic/Pgp-null crosses with histological amyloid quantification","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic KO combined with pharmacological inhibition and transgenic cross, multiple orthogonal in vivo approaches","pmids":["16239972"],"is_preprint":false},{"year":2006,"finding":"A synonymous SNP (C3435T) in MDR1/ABCB1, part of the 1236T-2677T-3435T haplotype, produces P-glycoprotein with altered drug and inhibitor interactions despite similar mRNA and protein levels; the polymorphic P-gp exhibits altered conformation, suggesting that a rare codon slows cotranslational folding and changes the structure of substrate and inhibitor interaction sites.","method":"Cell-based expression of wild-type vs. polymorphic P-gp, drug interaction assays, inhibitor interaction studies, conformational analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 — direct functional comparison of WT vs. SNP protein with mechanistic conformational explanation, >1880 citations","pmids":["17185560"],"is_preprint":false},{"year":2006,"finding":"P-glycoprotein localizes to both luminal and abluminal membranes of brain capillary endothelial cells as well as to adjacent pericytes and astrocytes; subcellularly it is distributed along the nuclear envelope, in caveolae, cytoplasmic vesicles, Golgi complex, and rough ER, consistent with roles in protein synthesis, glycosylation, membrane trafficking, and drug efflux at multiple BBB cell types.","method":"Immunogold cytochemistry at electron microscope level in rat and human brain tissues","journal":"The journal of histochemistry and cytochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular localization by EM immunogold, single study","pmids":["16801529"],"is_preprint":false},{"year":2007,"finding":"ATP binding at the interface of the two nucleotide-binding domains (NBDs) of P-glycoprotein induces formation of a closed NBD dimer, and the power-stroke for drug transport is provided only after formation of the pre-hydrolysis transition-like state during ATP hydrolysis; this catalytic mechanism couples NBD dimerization and ATP hydrolysis to conformational changes in the transmembrane domains that drive drug efflux.","method":"Mutational analysis of NBDs, biochemical ATP hydrolysis assays, structural studies with isolated NBDs, review synthesizing mechanistic data","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 1–2 — mutational and biochemical evidence, synthesis of structural and biochemical studies","pmids":["17237262"],"is_preprint":false},{"year":2007,"finding":"The linker domain of human ABCB1 (approximately 90 amino acids connecting the two halves) contains three polypeptide sequences (LDS617-627, LDS657-676, LDS693-705) that directly bind alpha- and beta-tubulins (identified as a ~57 kDa protein), providing the first evidence that ABCB1 interacts with intracellular cytoskeletal proteins via its linker domain.","method":"Overlapping hexapeptide binding assay spanning the linker domain, affinity purification, N-terminal amino acid sequencing, Western blot with anti-tubulin antibodies","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding assay with peptide identification and protein sequencing, single study","pmids":["17530867"],"is_preprint":false},{"year":2009,"finding":"Pro-inflammatory cytokines TNF-α increases P-glycoprotein mRNA and protein expression at the blood-brain barrier (hCMEC/D3 cells), while IL-6 slightly reduces it; these changes suggest inflammatory signaling regulates ABCB1 expression at the BBB.","method":"Cytokine treatment of hCMEC/D3 cells, qRT-PCR, Western blot, functional rhodamine 123 uptake assay","journal":"Cellular and molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 3 — cell-based expression and functional assay, single lab","pmids":["19629677"],"is_preprint":false},{"year":2011,"finding":"Sildenafil inhibits the drug efflux function of ABCB1 by stimulating its ATPase activity and competitively inhibiting photoaffinity labeling with [125I]-IAAP at the substrate-binding site, increasing intracellular concentration of ABCB1 substrate drugs (paclitaxel) in ABCB1-overexpressing cells; sildenafil does not alter ABCB1 protein expression.","method":"Cytotoxicity assays in ABCB1-overexpressing cells, intracellular drug accumulation measurements, ATPase activity assay, [125I]-IAAP photoaffinity labeling competition, homology modeling","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — ATPase assay plus photoaffinity labeling competition plus functional accumulation assay, multiple orthogonal methods","pmids":["21402712"],"is_preprint":false},{"year":2014,"finding":"P-glycoprotein was functionally reconstituted in giant proteoliposomes; active transport of rhodamine 123 required ATP (absent with verapamil or without ATP), and kinetic modeling revealed passive diffusion and active transport rate constants; patch-clamp on giant proteoliposomes also identified co-purifying chloride ion channel activity.","method":"Hydrogel-assisted reconstitution in giant proteoliposomes, fluorescence-based transport quantification, kinetic modeling, patch-clamp electrophysiology","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — direct reconstitution in defined lipid environment with functional validation and kinetic modeling","pmids":["25450342"],"is_preprint":false},{"year":2015,"finding":"ABCB1 exhibits structural flexibility in its inward-facing conformation (shown by multiple X-ray crystal structures with varying degrees of domain separation), and site-directed mutagenesis reveals multiple transport-active substrate binding sites within a large common drug-binding pocket, explaining the molecular basis of polyspecificity.","method":"X-ray crystallography (mouse P-gp), site-directed mutagenesis, biochemical and biophysical studies, molecular modeling","journal":"Advances in cancer research","confidence":"High","confidence_rationale":"Tier 1 — crystal structures plus mutagenesis, synthesis of multiple structural and biochemical studies","pmids":["25640267"],"is_preprint":false},{"year":2015,"finding":"ABCB1 and ABCG2 bind their allocrites (substrates) from the lipid membrane via a two-step mechanism: lipid-water partitioning driven by hydrophobic interactions, followed by transporter binding in the lipid bilayer driven by hydrogen bond acceptors in the substrate; the number of H-bond donors is higher in ABCG2 than ABCB1, explaining their different substrate affinities.","method":"Quantitative binding assays with 39 diverse compounds, transporter structural analysis, identification of H-bond donor residues in translocation pathways","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — systematic quantitative binding studies with structural analysis, single lab","pmids":["26381710"],"is_preprint":false},{"year":2015,"finding":"PET imaging with 11C-metoclopramide demonstrated that ABCB1 (P-gp) at the blood-brain barrier not only reduces drug influx into the brain but also actively mediates efflux from the brain back to blood (increased efflux rate constant k2 after P-gp inhibition with tariquidar), establishing a bidirectional transport role for ABCB1 at the BBB.","method":"11C-metoclopramide PET imaging in rats with/without tariquidar P-gp inhibition, 2-tissue-compartment kinetic modeling, in vitro P-gp/BCRP transport assays","journal":"Journal of nuclear medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo pharmacokinetic imaging with pharmacological inhibition and quantitative kinetic modeling","pmids":["26585058"],"is_preprint":false},{"year":2019,"finding":"Gut microbiota downregulates ABCB1 expression in the small intestine through polar bacterial metabolites and the Constitutive Androstane Receptor (CAR) transcription factor, thereby increasing tacrolimus bioavailability; antibiotic-mediated reduction of gut microbial load increases intestinal ABCB1 expression and reduces tacrolimus blood levels, while ABCB1 inhibition with zosuquidar abolishes this effect.","method":"Antibiotic-treated and germ-free mouse models, conventionalization experiments, in vivo zosuquidar ABCB1 inhibition, bacterial metabolite treatment, whole transcriptome analysis, in vitro microbiota-conditioned medium experiments","journal":"Microbiome","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vivo models (antibiotic, germ-free, reconstitution) with pharmacological validation","pmids":["37408070"],"is_preprint":false},{"year":2022,"finding":"USP7 (ubiquitin specific protease 7) is a deubiquitinating enzyme that directly interacts with ABCB1, stabilizes it by removing ubiquitin, and thereby increases ABCB1 protein levels and chemoresistance; USP7 knockdown reduces ABCB1 protein stability and sensitizes chemoresistant TNBC cells to doxorubicin.","method":"Co-immunoprecipitation, Western blot (ubiquitination assay), siRNA knockdown, USP7 inhibitor, overexpression, cell viability and apoptosis assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP demonstrating direct interaction plus functional knockdown/inhibitor validation, single lab","pmids":["36291159"],"is_preprint":false},{"year":2022,"finding":"CDK6 regulates ABCB1 expression through a CDK6-PI3K signaling axis; CDK6 knockout in KB-C2 cells dramatically downregulates ABCB1 mRNA and protein and reverses ABCB1-mediated MDR; this involves CDK6-dependent alternative splicing of premature ABCB1 mRNA, and CDK6 and PI3K110α/β act synergistically to regulate ABCB1 levels.","method":"CRISPR/Cas9 knockout of CDK6/CDK4/PI3K110α/110β, Western blot, RT-PCR, transcriptome analysis, flow cytometry, in vivo xenograft tumor experiments","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR KO with transcriptomic mechanistic follow-up and in vivo validation, single lab","pmids":["35459184"],"is_preprint":false},{"year":2019,"finding":"TGF-β1 upregulates P-glycoprotein (ABCB1) expression in hepatocellular carcinoma cells via a SMAD4/HOTAIR/miR-145 axis: TGF-β1 activates SMAD4 to induce HOTAIR lncRNA, which recruits EZH2 to suppress miR-145, and miR-145 directly suppresses ABCB1 translation by binding to the 3'-UTR of ABCB1 mRNA.","method":"siRNA knockdown of SMAD4/HOTAIR/EZH2, miR-145 overexpression/inhibition, luciferase 3'-UTR reporter assay (implied), Western blot, RT-PCR","journal":"Biopharmaceutics & drug disposition","confidence":"Medium","confidence_rationale":"Tier 2–3 — pathway dissection with multiple gene knockdowns, single lab","pmids":["30698830"],"is_preprint":false},{"year":2001,"finding":"P-glycoprotein expression in multidrug-resistant CEM/VBL100 cells sensitizes them specifically to mitochondria-mediated apoptosis (induced by TNF-α and staurosporine) correlated with mitochondrial membrane hyperpolarization, while simultaneously conferring resistance to Fas/CD95 and etoposide-induced apoptosis, revealing that ABCB1 expression shifts cell death pathways from plasma membrane-associated (type I) to mitochondria-associated (type II) apoptosis.","method":"Cell death assays with multiple proapoptotic stimuli, mitochondrial membrane potential measurement, MDR cell line comparison","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — multiple apoptotic stimuli with mitochondrial functional readout, single cell model","pmids":["11311119"],"is_preprint":false},{"year":2019,"finding":"ABCB1 is expressed at higher levels in multiple bat cell lines and tissues compared to human and mouse; efficient ABCB1-mediated drug efflux protects bat cells from DNA damage induced by genotoxic compounds (doxorubicin), as ABCB1 inhibition restores doxorubicin accumulation, DNA damage, and cell death in bat cells.","method":"Drug accumulation assays, ABCB1 inhibitor experiments, Western blot, DNA damage assays, cell death assays across multiple bat species cell lines","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition with functional readouts across multiple species and cell lines","pmids":["31249297"],"is_preprint":false},{"year":2019,"finding":"STAT5a transcription factor directly regulates ABCB1 transcription in breast cancer, with STAT5a and ABCB1 expression positively correlated; STAT5a knockdown reduces ABCB1 expression and doxorubicin resistance, and STAT5a overexpression increases ABCB1-mediated resistance.","method":"Western blot, ChIP or transcriptional reporter assay, siRNA knockdown, overexpression, in vivo xenograft experiments","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function and loss-of-function with in vivo validation, single lab","pmids":["34336684"],"is_preprint":false},{"year":2013,"finding":"Methadone acts as a non-competitive inhibitor of wild-type human P-glycoprotein (IC50 = 2.17 μM) and also stimulates P-gp ATPase activity; variant P-gp bearing the 1236T-2677T-3435T haplotype (or 1236T-2677A-3435T) shows reduced inhibition potency (IC50 = 2.97–4.43 μM) via uncompetitive kinetics, explaining higher methadone dose requirements in variant carriers.","method":"Stably transfected Flp-In-293 cells expressing wild-type or variant P-gp, rhodamine 123 efflux assay, calcein-AM uptake assay, P-gp ATPase assay, enzyme kinetic analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays in isogenic cell lines expressing defined genotypes, kinetic characterization","pmids":["23527191"],"is_preprint":false},{"year":2003,"finding":"Doxorubicin selectively induces mdr1b (but not mdr1a or mrp1) mRNA expression in rat astrocyte primary cultures in a time- and dose-dependent manner that is inhibited by actinomycin D, indicating transcriptional upregulation; the induced P-gp is functionally active, enhancing vincristine efflux that is blocked by P-gp inhibitors (PSC833, GW918) but not by the MRP1 inhibitor MK571.","method":"Northern blot (mRNA), Western blot (protein), functional vincristine efflux assay with selective inhibitors in primary rat astrocyte cultures","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — transcriptional and protein induction with functional validation using selective inhibitors","pmids":["14622113"],"is_preprint":false}],"current_model":"ABCB1/P-glycoprotein is a 1280-amino-acid integral membrane glycoprotein comprising two transmembrane domains (each with six transmembrane segments) and two nucleotide-binding domains that form a closed dimer upon ATP binding; ATP hydrolysis (requiring two ATPs per transport cycle) drives conformational changes that translocate structurally diverse hydrophobic substrates—including cytotoxic drugs, lipids (acting as a lipid flippase), steroids, and Aβ peptides—from the cytoplasm/inner membrane leaflet to the extracellular space or membrane outer leaflet; substrate polyspecificity arises from a large, flexible drug-binding pocket with multiple overlapping sites in the transmembrane domains; the linker domain mediates interaction with alpha/beta-tubulin; ABCB1 expression is regulated transcriptionally by nuclear receptors (CAR), cytokines (TNF-α), STAT5a, the gut microbiome via bacterial metabolites, and epigenetically via HOTAIR/miR-145; its protein stability is regulated post-translationally by the deubiquitinase USP7; and at the blood-brain barrier P-gp actively mediates both influx limitation and efflux of substrates from the CNS."},"narrative":{"teleology":[{"year":1986,"claim":"Cloning and transfection of MDR1 established that a single gene encodes a 1280-aa membrane glycoprotein with two TMD–NBD cassettes sufficient to confer the complete multidrug-resistance phenotype, resolving whether MDR required one or multiple gene products.","evidence":"cDNA sequencing, homology analysis, and gain-of-function transfection into drug-sensitive cells","pmids":["2876781","3768958","3022150"],"confidence":"High","gaps":["No atomic-resolution structure yet available","Substrate recognition mechanism unknown","Stoichiometry of ATP utilization not determined"]},{"year":1988,"claim":"Point mutations within ABCB1 that alter the drug cross-resistance profile demonstrated that substrate specificity is encoded within the P-glycoprotein sequence itself, not by accessory factors.","evidence":"Sequencing of spontaneous mdr1 mutants from colchicine-selected cells, site-directed mutagenesis, and drug resistance profiling","pmids":["2897240"],"confidence":"High","gaps":["Exact residues forming the drug-binding pocket not mapped","No structural basis for how single mutations shift specificity"]},{"year":1989,"claim":"Reconstitution of ATP-dependent, unidirectional daunomycin transport in membrane vesicles proved that P-glycoprotein is a bona fide ATP-driven efflux pump, ruling out channel or facilitator models.","evidence":"Canalicular and brush-border membrane vesicle transport assays with non-hydrolyzable ATP analogue controls","pmids":["2568355","1347031"],"confidence":"High","gaps":["Number of ATPs consumed per transport cycle not yet quantified","Lipid substrate transport not yet tested"]},{"year":1996,"claim":"Demonstration that ABCB1 translocates short-chain phospholipid and sphingolipid analogues to the outer leaflet expanded its function beyond drug efflux to a broad-specificity lipid flippase.","evidence":"Fluorescent lipid analogue translocation assays in stably transfected epithelial monolayers with energy-depletion and inhibitor controls","pmids":["8898203"],"confidence":"High","gaps":["Physiological relevance of lipid flippase activity in non-epithelial tissues unclear","Structural basis of lipid vs drug recognition not resolved"]},{"year":2000,"claim":"The C3435T synonymous SNP and the 1236T-2677T-3435T haplotype were linked to altered intestinal P-gp expression and drug pharmacokinetics, establishing that common ABCB1 genetic variants have functional consequences in vivo.","evidence":"Genotype–phenotype correlation in human volunteers using Western blot, immunohistology, digoxin/fexofenadine pharmacokinetics, and in vitro efflux assays of expressed alleles","pmids":["10716719","11503014"],"confidence":"High","gaps":["Causal SNP vs linkage disequilibrium not fully distinguished","Mechanism by which synonymous SNP alters expression/function unresolved"]},{"year":2003,"claim":"Synthesis of photoaffinity labeling, mutagenesis, and ATPase data established the two-ATP-per-substrate stoichiometry and located multiple overlapping drug-binding sites within the TMDs, providing a mechanistic framework for polyspecificity.","evidence":"Photoaffinity labeling with [125I]-IAAP, site-directed mutagenesis, ATPase measurements across multiple labs","pmids":["14576852"],"confidence":"High","gaps":["No high-resolution drug-bound structure","Allosteric coupling between binding pocket and NBDs not structurally resolved"]},{"year":2005,"claim":"Genetic ablation and pharmacological inhibition of P-gp at the BBB showed that ABCB1 mediates Aβ peptide clearance from the CNS, linking the transporter to Alzheimer's disease amyloid pathology.","evidence":"Radiolabeled Aβ microinjection in Pgp-null vs WT mice, P-gp inhibitor studies in APP-transgenic mice, histological amyloid quantification","pmids":["16239972"],"confidence":"High","gaps":["Whether ABCB1 transports Aβ directly or via an intermediary not fully resolved","Relevance to human AD progression not established"]},{"year":2006,"claim":"The 1236T-2677T-3435T haplotype was shown to alter P-gp conformation without changing expression levels, revealing that synonymous codon changes affect cotranslational folding and thereby substrate/inhibitor interaction profiles.","evidence":"Cell-based expression of WT vs polymorphic P-gp with drug interaction and conformational analysis","pmids":["17185560"],"confidence":"High","gaps":["Direct structural evidence for altered folding not obtained","Generalizability of cotranslational folding mechanism to other ABC transporters unknown"]},{"year":2007,"claim":"NBD dimerization studies showed that the power stroke for transport occurs upon formation of the pre-hydrolysis transition state, clarifying that it is ATP-dependent NBD closure—not hydrolysis product release—that drives the conformational switch.","evidence":"Mutational analysis of NBDs, biochemical ATP hydrolysis assays, structural studies with isolated NBDs","pmids":["17237262"],"confidence":"High","gaps":["Full-length structure in transition state not captured","Coupling pathway from NBDs to TMD drug-binding pocket not resolved at residue level"]},{"year":2015,"claim":"Crystal structures of mouse P-gp in multiple inward-facing conformations combined with mutagenesis defined the large, flexible drug-binding pocket and the structural basis of polyspecificity, while quantitative binding studies established a two-step lipid-partitioning/transporter-binding recognition mechanism.","evidence":"X-ray crystallography of mouse P-gp, site-directed mutagenesis, quantitative binding assays with 39 compounds","pmids":["25640267","26381710"],"confidence":"High","gaps":["Human P-gp high-resolution structure not yet available at this time","Outward-facing drug-release conformation not captured crystallographically"]},{"year":2015,"claim":"PET imaging with 11C-metoclopramide in living rats demonstrated that P-gp at the BBB actively mediates efflux (not just influx limitation), establishing bidirectional transport in vivo.","evidence":"PET imaging with/without tariquidar inhibition and two-tissue-compartment kinetic modeling","pmids":["26585058"],"confidence":"High","gaps":["Relative contribution of influx limitation vs active efflux for different substrates not quantified","Translation to human BBB PET not yet performed"]},{"year":2019,"claim":"Multiple transcriptional and post-transcriptional regulatory axes were delineated: gut microbiota suppress intestinal ABCB1 via CAR, TGF-β1 upregulates it through the SMAD4/HOTAIR/miR-145 cascade, and STAT5a directly activates ABCB1 transcription in breast cancer.","evidence":"Germ-free/antibiotic mouse models with ABCB1 inhibitor rescue; siRNA knockdowns of SMAD4/HOTAIR/EZH2 with miR-145 reporter assays; STAT5a ChIP and gain/loss-of-function with xenograft validation","pmids":["37408070","30698830","34336684"],"confidence":"Medium","gaps":["Integration of these regulatory inputs in the same cellular context not tested","Relative quantitative contribution of each pathway to total ABCB1 expression unknown","CAR-binding site in ABCB1 promoter not mapped"]},{"year":2022,"claim":"USP7 was identified as a deubiquitinase that directly interacts with and stabilizes ABCB1, and CDK6 was shown to regulate ABCB1 through a PI3K-dependent axis involving alternative splicing, revealing post-translational and co-transcriptional control layers.","evidence":"Co-IP, ubiquitination assays, siRNA/inhibitor studies for USP7; CRISPR KO of CDK6/PI3K with transcriptomic and in vivo xenograft validation","pmids":["36291159","35459184"],"confidence":"Medium","gaps":["USP7 interaction validated in a single lab; reciprocal IP and structural interface not defined","CDK6-dependent splicing mechanism not molecularly characterized","Whether USP7 and CDK6 pathways interact is unknown"]},{"year":null,"claim":"Key unresolved questions include the precise structural mechanism coupling drug binding to the NBD power stroke in the human protein, the physiological significance of the tubulin–linker interaction, and how multiple transcriptional/post-translational inputs are integrated to set ABCB1 expression levels in specific tissues.","evidence":"","pmids":[],"confidence":"High","gaps":["High-resolution cryo-EM structures of human ABCB1 in multiple conformational states with bound clinical substrates needed","Functional role of tubulin binding via the linker domain not tested by mutagenesis in transport assays","Systems-level integration of regulatory inputs (CAR, STAT5a, miR-145, USP7, CDK6) in primary human tissues not addressed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,3,4,8,12,16]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,1,3,4,5,8,9,16]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[5,18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,4,5,6,11]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[11]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[11]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[11]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,1,3,4,5,8,9,16]},{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[6,7,10,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,22,24]}],"complexes":[],"partners":["TUBA1A","TUBB","USP7"],"other_free_text":[]},"mechanistic_narrative":"ABCB1 (P-glycoprotein/MDR1) is an ATP-dependent efflux transporter that uses the energy of ATP hydrolysis to translocate a broad spectrum of hydrophobic substrates—including cytotoxic drugs, lipids, and amyloid-β peptides—from the cytoplasmic face of the membrane to the extracellular space, thereby conferring multidrug resistance and regulating substrate bioavailability across pharmacological barriers [PMID:2876781, PMID:3022150, PMID:2568355, PMID:8898203, PMID:16239972]. Substrate polyspecificity arises from a large, flexible drug-binding pocket within the transmembrane domains containing multiple overlapping sites, while ATP-driven closure of the two nucleotide-binding domains into a sandwich dimer couples hydrolysis of two ATP molecules per transport cycle to conformational changes that power unidirectional efflux [PMID:14576852, PMID:17237262, PMID:25640267]. At the blood–brain barrier, ABCB1 mediates both influx limitation and active efflux of substrates including Aβ peptides, and its loss increases cerebral amyloid deposition [PMID:16239972, PMID:26585058]. ABCB1 expression is regulated transcriptionally by nuclear receptors (CAR), cytokines, STAT5a, and the HOTAIR/miR-145 axis, and post-translationally by USP7-mediated deubiquitination that controls protein stability [PMID:37408070, PMID:34336684, PMID:30698830, PMID:36291159]."},"prefetch_data":{"uniprot":{"accession":"P08183","full_name":"ATP-dependent translocase ABCB1","aliases":["ATP-binding cassette sub-family B member 1","Multidrug resistance protein 1","P-glycoprotein 1","Phospholipid transporter ABCB1"],"length_aa":1280,"mass_kda":141.5,"function":"Translocates drugs and phospholipids across the membrane (PubMed:2897240, PubMed:35970996, PubMed:8898203, PubMed:9038218, PubMed:35507548). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:35970996, PubMed:9038218)","subcellular_location":"Cell membrane; Apical cell membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P08183/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABCB1","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2},{"gene":"RAB11A","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ABCB1","total_profiled":1310},"omim":[{"mim_id":"620950","title":"ENCEPHALOPATHY, ACUTE TRANSIENT; ENPAT","url":"https://www.omim.org/entry/620950"},{"mim_id":"619612","title":"B-CELL RECEPTOR-ASSOCIATED PROTEIN 29; BCAP29","url":"https://www.omim.org/entry/619612"},{"mim_id":"615902","title":"PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B-DOUBLE PRIME, GAMMA; PPP2R3C","url":"https://www.omim.org/entry/615902"},{"mim_id":"614914","title":"MICRO RNA 298; MIR298","url":"https://www.omim.org/entry/614914"},{"mim_id":"614546","title":"EFAVIRENZ, POOR METABOLISM OF","url":"https://www.omim.org/entry/614546"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":96.1},{"tissue":"intestine","ntpm":66.6}],"url":"https://www.proteinatlas.org/search/ABCB1"},"hgnc":{"alias_symbol":["P-gp","CD243","GP170","ABC20","p-170","PGY1"],"prev_symbol":["PGY1","MDR1","CLCS"]},"alphafold":{"accession":"P08183","domains":[{"cath_id":"1.20.1560.10","chopping":"212-325_684-851_972-1021","consensus_level":"medium","plddt":87.4578,"start":212,"end":1021},{"cath_id":"3.40.50.300","chopping":"391-631","consensus_level":"medium","plddt":89.7837,"start":391,"end":631},{"cath_id":"3.40.50.300","chopping":"1034-1274","consensus_level":"medium","plddt":89.7515,"start":1034,"end":1274}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08183","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08183-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08183-F1-predicted_aligned_error_v6.png","plddt_mean":84.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABCB1","jax_strain_url":"https://www.jax.org/strain/search?query=ABCB1"},"sequence":{"accession":"P08183","fasta_url":"https://rest.uniprot.org/uniprotkb/P08183.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08183/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08183"}},"corpus_meta":[{"pmid":"22257057","id":"PMC_22257057","title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds.","date":"2012","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22257057","citation_count":417,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9214671","id":"PMC_9214671","title":"Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.","date":"1997","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/9214671","citation_count":351,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2568355","id":"PMC_2568355","title":"The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2568355","citation_count":312,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17898703","id":"PMC_17898703","title":"Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief.","date":"2007","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17898703","citation_count":245,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16143395","id":"PMC_16143395","title":"Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation.","date":"2005","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/16143395","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16352426","id":"PMC_16352426","title":"The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).","date":"2005","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16352426","citation_count":168,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16801529","id":"PMC_16801529","title":"In situ localization of P-glycoprotein (ABCB1) in human and rat brain.","date":"2006","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/16801529","citation_count":166,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19629677","id":"PMC_19629677","title":"Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.","date":"2009","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19629677","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15228162","id":"PMC_15228162","title":"Clinical aspects of the MDR1 (ABCB1) gene polymorphism.","date":"2004","source":"Therapeutic drug monitoring","url":"https://pubmed.ncbi.nlm.nih.gov/15228162","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21402712","id":"PMC_21402712","title":"Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21402712","citation_count":143,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1347031","id":"PMC_1347031","title":"The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa.","date":"1992","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/1347031","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15217301","id":"PMC_15217301","title":"The MDR1 (ABCB1) gene polymorphism and its clinical implications.","date":"2004","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/15217301","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17237262","id":"PMC_17237262","title":"About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work.","date":"2007","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17237262","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31921655","id":"PMC_31921655","title":"Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31921655","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18288958","id":"PMC_18288958","title":"Genuine functions of P-glycoprotein (ABCB1).","date":"2008","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18288958","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25640267","id":"PMC_25640267","title":"Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies.","date":"2015","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25640267","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23861346","id":"PMC_23861346","title":"Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23861346","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22549467","id":"PMC_22549467","title":"Regulation of ABCB1/PGP1-catalysed auxin transport by linker phosphorylation.","date":"2012","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22549467","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17259950","id":"PMC_17259950","title":"ABCB1 pharmacogenetics: progress, pitfalls, and promise.","date":"2007","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17259950","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15212152","id":"PMC_15212152","title":"Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1).","date":"2004","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/15212152","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15917342","id":"PMC_15917342","title":"Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection.","date":"2005","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/15917342","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17451894","id":"PMC_17451894","title":"Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.","date":"2007","source":"International journal of pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/17451894","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30315846","id":"PMC_30315846","title":"Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30315846","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17593551","id":"PMC_17593551","title":"Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.","date":"2007","source":"Journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17593551","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19442042","id":"PMC_19442042","title":"Recent advances in the development of P-gp inhibitors.","date":"2009","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19442042","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17187507","id":"PMC_17187507","title":"Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.","date":"2007","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/17187507","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24107928","id":"PMC_24107928","title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.","date":"2013","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24107928","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24687344","id":"PMC_24687344","title":"MDR1 (ABCB1) polymorphisms: functional effects and clinical implications.","date":"2013","source":"Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion","url":"https://pubmed.ncbi.nlm.nih.gov/24687344","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15247630","id":"PMC_15247630","title":"Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms.","date":"2004","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15247630","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15911222","id":"PMC_15911222","title":"Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?","date":"2005","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15911222","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20555295","id":"PMC_20555295","title":"ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression.","date":"2010","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20555295","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9054575","id":"PMC_9054575","title":"Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9054575","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16842213","id":"PMC_16842213","title":"MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.","date":"2006","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/16842213","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25915534","id":"PMC_25915534","title":"Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25915534","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18058211","id":"PMC_18058211","title":"Genomics and the mechanism of P-glycoprotein (ABCB1).","date":"2007","source":"Journal of bioenergetics and biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/18058211","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21660212","id":"PMC_21660212","title":"Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice.","date":"2011","source":"International journal of Alzheimer's disease","url":"https://pubmed.ncbi.nlm.nih.gov/21660212","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37686513","id":"PMC_37686513","title":"Genetics of ABCB1 in Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37686513","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31801248","id":"PMC_31801248","title":"Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31801248","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31078601","id":"PMC_31078601","title":"Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31078601","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26869442","id":"PMC_26869442","title":"Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9.","date":"2016","source":"Journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26869442","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17933685","id":"PMC_17933685","title":"Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects.","date":"2007","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/17933685","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26197160","id":"PMC_26197160","title":"Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.","date":"2015","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26197160","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24703092","id":"PMC_24703092","title":"Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption.","date":"2014","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/24703092","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29317984","id":"PMC_29317984","title":"P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease.","date":"2017","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/29317984","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35459184","id":"PMC_35459184","title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35459184","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26585058","id":"PMC_26585058","title":"Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.","date":"2015","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26585058","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27262378","id":"PMC_27262378","title":"Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines.","date":"2016","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27262378","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19415305","id":"PMC_19415305","title":"ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.","date":"2009","source":"International journal of colorectal disease","url":"https://pubmed.ncbi.nlm.nih.gov/19415305","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30698830","id":"PMC_30698830","title":"TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis.","date":"2019","source":"Biopharmaceutics & drug disposition","url":"https://pubmed.ncbi.nlm.nih.gov/30698830","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18950875","id":"PMC_18950875","title":"Human pharmaceuticals modulate P-gp1 (ABCB1) transport activity in the fish cell line PLHC-1.","date":"2008","source":"Aquatic toxicology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/18950875","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37408070","id":"PMC_37408070","title":"Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1.","date":"2023","source":"Microbiome","url":"https://pubmed.ncbi.nlm.nih.gov/37408070","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22464980","id":"PMC_22464980","title":"Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux.","date":"2012","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22464980","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32517082","id":"PMC_32517082","title":"Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32517082","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31249297","id":"PMC_31249297","title":"ABCB1 protects bat cells from DNA damage induced by genotoxic compounds.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31249297","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31941029","id":"PMC_31941029","title":"Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31941029","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30280663","id":"PMC_30280663","title":"Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.","date":"2019","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30280663","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30789308","id":"PMC_30789308","title":"Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics.","date":"2019","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30789308","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18922637","id":"PMC_18922637","title":"Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics.","date":"2008","source":"Veterinary parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/18922637","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33543229","id":"PMC_33543229","title":"Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/33543229","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19196542","id":"PMC_19196542","title":"Association of a polymorphism in the ABCB1 gene with Parkinson's disease.","date":"2009","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/19196542","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25640268","id":"PMC_25640268","title":"Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.","date":"2015","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25640268","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35008783","id":"PMC_35008783","title":"Structure-Function Relationships in the Human P-Glycoprotein (ABCB1): Insights from Molecular Dynamics Simulations.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35008783","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27897269","id":"PMC_27897269","title":"An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.","date":"2016","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/27897269","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28303028","id":"PMC_28303028","title":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.","date":"2017","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28303028","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19772851","id":"PMC_19772851","title":"P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil.","date":"2009","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/19772851","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23527191","id":"PMC_23527191","title":"Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23527191","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30641875","id":"PMC_30641875","title":"Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30641875","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27588398","id":"PMC_27588398","title":"ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27588398","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20664232","id":"PMC_20664232","title":"Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study.","date":"2010","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/20664232","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17933684","id":"PMC_17933684","title":"Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects.","date":"2007","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/17933684","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21366702","id":"PMC_21366702","title":"P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components.","date":"2011","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21366702","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28265007","id":"PMC_28265007","title":"The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.","date":"2017","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28265007","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31500210","id":"PMC_31500210","title":"Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31500210","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32186270","id":"PMC_32186270","title":"Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.","date":"2020","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/32186270","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28101689","id":"PMC_28101689","title":"Gene Therapeutic Approaches to Overcome ABCB1-Mediated Drug Resistance.","date":"2016","source":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28101689","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25487678","id":"PMC_25487678","title":"ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.","date":"2014","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/25487678","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32903706","id":"PMC_32903706","title":"Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32903706","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17530867","id":"PMC_17530867","title":"The P-glycoprotein (ABCB1) linker domain encodes high-affinity binding sequences to alpha- and beta-tubulins.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17530867","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28189906","id":"PMC_28189906","title":"Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells.","date":"2017","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28189906","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24192121","id":"PMC_24192121","title":"ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients.","date":"2013","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/24192121","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19290795","id":"PMC_19290795","title":"CYP3A5 and ABCB1 genes and hypertension.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19290795","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36291159","id":"PMC_36291159","title":"USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36291159","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24980806","id":"PMC_24980806","title":"Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.","date":"2014","source":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","url":"https://pubmed.ncbi.nlm.nih.gov/24980806","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28534954","id":"PMC_28534954","title":"Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance.","date":"2017","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28534954","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14622113","id":"PMC_14622113","title":"P-glycoprotein (ABCB1) but not multidrug resistance-associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytes.","date":"2003","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14622113","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25437111","id":"PMC_25437111","title":"Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin.","date":"2014","source":"International journal of pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/25437111","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26381710","id":"PMC_26381710","title":"Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1).","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26381710","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27268766","id":"PMC_27268766","title":"ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib.","date":"2016","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/27268766","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34347777","id":"PMC_34347777","title":"Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34347777","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25660379","id":"PMC_25660379","title":"Identification of a nonsense mutation in feline ABCB1.","date":"2015","source":"Journal of veterinary pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25660379","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25450342","id":"PMC_25450342","title":"Hydrogel-assisted functional reconstitution of human P-glycoprotein (ABCB1) in giant liposomes.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25450342","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22900779","id":"PMC_22900779","title":"The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP.","date":"2012","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/22900779","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18075465","id":"PMC_18075465","title":"Promoter polymorphisms and allelic imbalance in ABCB1 expression.","date":"2007","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18075465","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11311119","id":"PMC_11311119","title":"Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11311119","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25430046","id":"PMC_25430046","title":"Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites.","date":"2014","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25430046","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24002095","id":"PMC_24002095","title":"Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro.","date":"2013","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/24002095","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34336684","id":"PMC_34336684","title":"STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34336684","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26681082","id":"PMC_26681082","title":"OPRM1 and ABCB1 polymorphisms and their effect on postoperative pain relief with piritramide.","date":"2015","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/26681082","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33910062","id":"PMC_33910062","title":"Dietary bioactive diindolylmethane enhances the therapeutic efficacy of centchroman in breast cancer cells by regulating ABCB1/P-gp efflux transporter.","date":"2021","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33910062","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33921129","id":"PMC_33921129","title":"Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/33921129","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2876781","id":"PMC_2876781","title":"Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.","date":"1986","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2876781","citation_count":1895,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17185560","id":"PMC_17185560","title":"A \"silent\" polymorphism in the MDR1 gene changes substrate specificity.","date":"2006","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17185560","citation_count":1887,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10716719","id":"PMC_10716719","title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10716719","citation_count":1772,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30280653","id":"PMC_30280653","title":"Blood-Brain Barrier: From Physiology to Disease and Back.","date":"2019","source":"Physiological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30280653","citation_count":1645,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19106083","id":"PMC_19106083","title":"Genetic determinants of response to clopidogrel and cardiovascular events.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19106083","citation_count":1335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26590417","id":"PMC_26590417","title":"Establishment and Dysfunction of the Blood-Brain Barrier.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26590417","citation_count":1304,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3768958","id":"PMC_3768958","title":"Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins.","date":"1986","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3768958","citation_count":1021,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14576852","id":"PMC_14576852","title":"P-glycoprotein: from genomics to mechanism.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14576852","citation_count":869,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11503014","id":"PMC_11503014","title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans.","date":"2001","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11503014","citation_count":836,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11076863","id":"PMC_11076863","title":"DNA cloning using in vitro site-specific recombination.","date":"2000","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/11076863","citation_count":815,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3022150","id":"PMC_3022150","title":"Isolation and expression of a complementary DNA that confers multidrug resistance.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3022150","citation_count":814,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8898203","id":"PMC_8898203","title":"MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8898203","citation_count":751,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20801498","id":"PMC_20801498","title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.","date":"2010","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20801498","citation_count":634,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11240981","id":"PMC_11240981","title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.","date":"2001","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11240981","citation_count":626,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12966368","id":"PMC_12966368","title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.","date":"2003","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12966368","citation_count":579,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16239972","id":"PMC_16239972","title":"P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16239972","citation_count":541,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11809184","id":"PMC_11809184","title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.","date":"2002","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11809184","citation_count":530,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15622315","id":"PMC_15622315","title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.","date":"2004","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15622315","citation_count":516,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12686700","id":"PMC_12686700","title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.","date":"2003","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12686700","citation_count":484,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20801494","id":"PMC_20801494","title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.","date":"2010","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20801494","citation_count":483,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11356939","id":"PMC_11356939","title":"Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.","date":"2001","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11356939","citation_count":448,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2897240","id":"PMC_2897240","title":"An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene.","date":"1988","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2897240","citation_count":436,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12493773","id":"PMC_12493773","title":"Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12493773","citation_count":430,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51527,"output_tokens":5536,"usd":0.11881},"stage2":{"model":"claude-opus-4-6","input_tokens":9078,"output_tokens":3428,"usd":0.196635},"total_usd":0.681327,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66102,"output_tokens":7093,"usd":0.15235},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11071,"output_tokens":3480,"usd":0.213532}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"Gp170/P-glycoprotein (ABCB1) in rat liver canalicular membrane vesicles functions as an ATP-dependent efflux pump for cytotoxic drugs (daunomycin), requiring ATP hydrolysis (non-hydrolyzable analogues were ineffective), operating in a unidirectional (inside-out) manner, temperature-dependent and osmotically sensitive fashion, and inhibited by verapamil, quinidine, vinblastine, vincristine, and adriamycin.\",\n      \"method\": \"ATP-dependent transport assay in inside-out vs. right-side-out canalicular membrane vesicles; antibody-induced affinity density perturbation; inhibitor studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted vesicle transport assay with multiple orthogonal controls (orientation, temperature, nucleotide specificity, pharmacological inhibition)\",\n      \"pmids\": [\"2568355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Gp170/P-glycoprotein (ABCB1) in rat small intestinal brush border membrane vesicles (but not basolateral membrane vesicles) functions as an ATP-dependent efflux pump transporting substrates from intracellular to luminal space; everted intestinal preparations confirmed directional transport of rhodamine 123 from serosal to mucosal side, blocked by Gp170 inhibitors.\",\n      \"method\": \"ATP-dependent transport assay in jejunal/ileal brush border vesicles; everted small intestine transport assay; inhibitor studies\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted vesicle and intact tissue transport assays with multiple controls and pharmacological inhibitors\",\n      \"pmids\": [\"1347031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ABCB1/P-glycoprotein mechanism involves two nucleotide-binding domains (NBDs) and two transmembrane domains; ATP binds at the interface of the two NBDs inducing closed dimer formation, and ATP hydrolysis is coupled to drug efflux via conformational changes; conserved amino acids in the NBDs are critical for catalysis; the drug-binding pocket in the transmembrane domains is large and accommodates multiple overlapping substrate-binding sites.\",\n      \"method\": \"Biochemical assays, site-directed mutagenesis of NBD residues, structural studies with non-mammalian ABC protein homologs, photolabeling studies\",\n      \"journal\": \"European journal of pharmaceutical sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical and mutagenesis approaches, extensively replicated across labs\",\n      \"pmids\": [\"16352426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"P-glycoprotein (ABCB1) ATP hydrolysis cycle involves ATP binding at the NBD interface inducing closed dimer formation providing the power stroke only after formation of the pre-hydrolysis transition-like (E·S) state; both NBDs are required for catalytic activity.\",\n      \"method\": \"Mutational analysis of NBDs combined with biochemical ATP hydrolysis assays; structural studies with isolated NBDs of bacterial ABC transporters\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NBD mutagenesis combined with structural data, multiple labs contributing\",\n      \"pmids\": [\"17237262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"P-glycoprotein (ABCB1) localizes to both luminal and abluminal membranes of brain capillary endothelial cells, as well as to adjacent pericytes and astrocyte plasma membranes; subcellularly it is present along the nuclear envelope, in caveolae, cytoplasmic vesicles, Golgi complex, and rough endoplasmic reticulum, consistent with sites of synthesis, glycosylation, and membrane trafficking.\",\n      \"method\": \"Immunogold cytochemistry at electron microscope level in rat and human brain tissues\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — high-resolution direct localization by electron microscopy in two species\",\n      \"pmids\": [\"16801529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sildenafil inhibits the drug efflux function of ABCB1 by stimulating ABCB1 ATPase activity and competing for the substrate-binding site (inhibiting [(125)I]-IAAP photolabeling of ABCB1), thereby increasing intracellular accumulation of ABCB1 substrate drugs such as paclitaxel in ABCB1-overexpressing cells.\",\n      \"method\": \"ATPase activity assay; IAAP photolabeling competition assay; intracellular drug accumulation assays; homology modeling\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ATPase assay and photolabeling together establish direct binding to substrate site; multiple orthogonal methods\",\n      \"pmids\": [\"21402712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The linker domain of human ABCB1 (the ~90 amino acid charged region connecting the two halves) contains sequences that directly bind alpha- and beta-tubulins; three specific polypeptide sequences (residues 617-627, 657-676, and 693-705) interact with a ~57 kDa intracellular protein identified by N-terminal sequencing as alpha/beta-tubulin.\",\n      \"method\": \"Overlapping hexapeptide binding assay; protein purification; N-terminal amino acid sequencing; Western blotting with anti-tubulin antibodies\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated by orthogonal methods (peptide binding + purification + sequencing + Western blot) but single lab study\",\n      \"pmids\": [\"17530867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Multiple X-ray crystal structures of mouse P-gp reveal that the protein adopts inward-facing conformations with different degrees of domain separation, demonstrating structural flexibility; site-directed mutagenesis reveals multiple transport-active binding sites for single substrates, with drugs able to bind at primary or secondary sites within a large common drug-binding pocket.\",\n      \"method\": \"X-ray crystallography; site-directed mutagenesis; biochemical binding assays; molecular modeling\",\n      \"journal\": \"Advances in cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures combined with mutagenesis and biochemical validation across multiple labs\",\n      \"pmids\": [\"25640267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Pro-inflammatory cytokines (TNF-alpha) increase P-glycoprotein (ABCB1) mRNA and protein expression in human blood-brain barrier endothelial cells (hCMEC/D3 cell line), indicating that inflammation can upregulate ABCB1 at the BBB, potentially altering drug penetration into the brain.\",\n      \"method\": \"mRNA quantification; protein expression analysis; functional uptake assay (rhodamine 123) in human BBB cell line\",\n      \"journal\": \"Cellular and molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — expression and functional assay in human BBB model, single lab, moderate confidence\",\n      \"pmids\": [\"19629677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Beta-amyloid (Abeta1-42) administration in mice significantly reduces P-glycoprotein (ABCB1) mRNA expression at the blood-brain barrier, suggesting that amyloid itself downregulates ABCB1, which could impair Abeta clearance and exacerbate neurodegeneration.\",\n      \"method\": \"In vivo subcutaneous Abeta administration via osmotic pumps; mRNA quantification by qRT-PCR in mouse brain\",\n      \"journal\": \"International journal of Alzheimer's disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo experiment with specific phenotypic readout but single lab and single method\",\n      \"pmids\": [\"21660212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Methadone acts as a non-competitive inhibitor of wild-type human P-glycoprotein (ABCB1) and stimulates P-gp ATPase activity; ABCB1 variants carrying the 1236T-2677T-3435T and 1236T-2677A-3435T haplotypes show reduced inhibition potency by methadone (uncompetitive kinetics and higher IC50), indicating that these polymorphisms affect the interaction between methadone and the transporter.\",\n      \"method\": \"Stably transfected Flp-In-293 cells expressing specific ABCB1 genotypes; rhodamine 123 efflux assay; calcein-AM uptake assay; P-gp ATPase assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in isogenic transfected cell lines, single lab\",\n      \"pmids\": [\"23527191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ABCB1 was functionally reconstituted into giant proteoliposomes; active transport of rhodamine 123 was demonstrated to require ATP (rate constant kT significantly higher with ATP vs. without ATP or with ATP plus verapamil inhibitor), quantifying passive diffusion and active transport rates separately; patch clamp on giant proteoliposomes revealed co-purifying chloride ion channel activity.\",\n      \"method\": \"Hydrogel-assisted giant proteoliposome formation; fluorescence-based transport assay with kinetic modeling; patch clamp electrophysiology\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution in defined lipid bilayer with quantitative kinetic analysis and multiple controls\",\n      \"pmids\": [\"25450342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCB1 (P-gp) binds its allocrites (substrates) from the lipid membrane in a two-step process: first lipid-water partitioning driven by hydrophobic interactions, then binding within the lipid bilayer; binding affinity increases with the number of hydrogen bond acceptors in the allocrite; the transmembrane translocation pathway contains ample hydrogen bond donors for substrate binding.\",\n      \"method\": \"Quantitative biochemical binding measurements for 39 diverse compounds; analysis of available transporter structures; structure-activity relationship analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — quantitative binding data across large compound set with structural analysis, single lab\",\n      \"pmids\": [\"26381710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP7 (ubiquitin-specific protease 7) is a deubiquitinating enzyme for ABCB1; USP7 directly interacts with ABCB1 and stabilizes the ABCB1 protein by removing ubiquitin, thereby promoting chemoresistance in triple-negative breast cancer.\",\n      \"method\": \"Co-immunoprecipitation; siRNA knockdown; USP7 inhibitor treatment; Western blot; apoptosis and metastasis assays; in vivo xenograft studies\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP establishes direct interaction, functional consequences validated by KD and inhibitor, single lab\",\n      \"pmids\": [\"36291159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"STAT5a transcriptionally regulates ABCB1 expression; STAT5a overexpression increases ABCB1 levels and doxorubicin resistance in breast cancer cells, while STAT5a knockdown reduces ABCB1 expression and restores chemosensitivity; pimozide (STAT5a inhibitor) recapitulates STAT5a KD effects.\",\n      \"method\": \"STAT5a overexpression and knockdown; Western blot and RT-PCR for ABCB1; chemosensitivity assays; in vivo xenograft experiments\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transcriptional regulation established by KD/OE with defined phenotypic readout and in vivo validation, single lab\",\n      \"pmids\": [\"34336684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The gut microbiota downregulates ABCB1 expression in the small intestine via polar bacterial metabolites and through the Constitutive Androstane Receptor (CAR) transcription factor; reduced microbial load (by antibiotics) leads to higher intestinal ABCB1 expression and lower tacrolimus blood exposure; functional ABCB1 inhibition by zosuquidar in vivo confirmed ABCB1 as the mediator of microbiota's effect on tacrolimus pharmacokinetics.\",\n      \"method\": \"In vivo mouse models (antibiotic-treated, germ-free, conventionalized); ABCB1 functional inhibition with zosuquidar; in vitro bacterial metabolite treatment; whole transcriptome analysis; germ-free mouse conventionalization\",\n      \"journal\": \"Microbiome\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo models with genetic/pharmacological validation of ABCB1 role; mechanistic pathway identified\",\n      \"pmids\": [\"37408070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TGF-β1 upregulates ABCB1 (P-gp) expression in hepatocellular carcinoma cells through the SMAD4/HOTAIR/miR-145 axis; miR-145 directly suppresses ABCB1 by binding to the 3'-UTR of ABCB1 mRNA; EZH2 controls miR-145 levels downstream of HOTAIR.\",\n      \"method\": \"siRNA knockdown of SMAD4 and EZH2; HOTAIR silencing; miR-145 overexpression; 3'-UTR reporter assay; Western blot; RT-PCR\",\n      \"journal\": \"Biopharmaceutics & drug disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — 3'-UTR binding and epistasis established by multiple loss-of-function experiments, single lab\",\n      \"pmids\": [\"30698830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CDK6 (via the CDK6-PI3K signaling axis) positively regulates ABCB1 expression; CDK6 knockout by CRISPR/Cas9 downregulates ABCB1 and reverses ABCB1-mediated multidrug resistance; the CDK6-PI3K axis acts through alternative splicing of premature ABCB1 mRNA (skipped exon events); CDK6 and PI3K110α/β have a synergistic effect on ABCB1 expression.\",\n      \"method\": \"CRISPR/Cas9 knockout of cdk6 and cdk4; Western blot and RT-PCR; transcriptome and alternative splicing analysis; flow cytometry; in vivo xenograft studies\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with transcriptomic mechanism identified, in vivo validation, single lab\",\n      \"pmids\": [\"35459184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Doxorubicin induces ABCB1 (mdr1b) upregulation in rat astrocytes in a time- and dose-dependent manner at the mRNA level (blocked by actinomycin D, indicating transcriptional regulation), leading to functional increase in P-gp-mediated vincristine efflux; this induction is selective for mdr1b over mdr1a and MRP1.\",\n      \"method\": \"Northern blot; actinomycin D transcription inhibition; Western blot; vincristine efflux assay with P-gp (PSC833, GW918) and MRP1 (MK571) inhibitors in rat astrocyte primary cultures\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transcriptional induction and functional consequence established with multiple methods, single lab\",\n      \"pmids\": [\"14622113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CRISPR-Cas9-mediated complete knockout of endogenous canine Mdr1/Abcb1 in MDCK cells eliminates directional drug transport (efflux ratios collapse to ~1 for digoxin and other MDR1 substrates), directly demonstrating that ABCB1 is responsible for polarized apical efflux transport in these epithelial cells.\",\n      \"method\": \"CRISPR-Cas9 gene editing; genome sequencing; quantitative protein analysis; bidirectional transport assays with prototypic MDR1 substrates\",\n      \"journal\": \"Journal of pharmaceutical sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complete genetic ablation with quantitative transport assay demonstrating unambiguous causal role; well-controlled loss-of-function\",\n      \"pmids\": [\"26869442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PET imaging with (11)C-metoclopramide demonstrated that P-gp (ABCB1) at the blood-brain barrier not only reduces influx into the brain but also actively mediates efflux from brain back to blood; P-gp inhibition with tariquidar increased influx rate constant (K1) 4.4-fold and decreased efflux rate (k2) 2.3-fold.\",\n      \"method\": \"11C-metoclopramide PET imaging in rats; kinetic modeling (2-tissue compartment model, Logan plot); P-gp inhibition with tariquidar; radio-HPLC analysis of metabolites\",\n      \"journal\": \"Journal of nuclear medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo PET with pharmacological inhibition and rigorous kinetic modeling; bidirectional transport function of ABCB1 at BBB directly demonstrated\",\n      \"pmids\": [\"26585058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABCB1 1199G>A SNP (rs2229109, Ser400Asn) results in more efficient transport of imatinib, nilotinib, and dasatinib; cells expressing the variant Asn400 protein showed lower intracellular accumulation of imatinib and nilotinib and reduced antiproliferative effects of all three TKIs compared to wild-type Ser400.\",\n      \"method\": \"Stable transfection of HEK293 and K562 cells with wild-type vs. variant ABCB1; intracellular drug accumulation assays; antiproliferative assays\",\n      \"journal\": \"Pharmacogenomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isogenic transfected cell lines with functional transport and cytotoxicity assays, single lab\",\n      \"pmids\": [\"27268766\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCB1/P-glycoprotein is an ATP-binding cassette efflux transporter in which substrates partition from the lipid bilayer into a large, flexible transmembrane drug-binding pocket with multiple overlapping sites; ATP binds at the interface of the two nucleotide-binding domains (NBDs), induces NBD dimerization, and the energy of ATP hydrolysis (provided at the pre-hydrolysis transition state) drives conformational changes that expel substrates against their concentration gradient toward the extracellular space or lumen—a function that limits oral drug absorption, mediates biliary/intestinal secretion, restricts CNS drug penetration by both reducing influx and actively promoting efflux at the blood-brain barrier, and whose expression is regulated transcriptionally by cytokines, gut microbial metabolites (via CAR), STAT5a, CDK6-PI3K signaling, and post-translationally by USP7-mediated deubiquitination.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"The MDR1/ABCB1 gene encodes a 1280 amino acid membrane glycoprotein (P-glycoprotein) consisting of two homologous halves, each with six predicted transmembrane segments and a hydrophilic nucleotide-binding domain homologous to bacterial active transport proteins, consistent with a function as an energy-dependent efflux pump.\",\n      \"method\": \"cDNA sequencing, sequence analysis and homology comparison\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational structural characterization, independently replicated, >1800 citations\",\n      \"pmids\": [\"2876781\", \"3768958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Overexpression of a single full-length mdr1 cDNA clone in drug-sensitive cells is sufficient to confer a complete multidrug-resistant phenotype, establishing that ABCB1 alone mediates multidrug resistance.\",\n      \"method\": \"cDNA transfection and drug resistance phenotyping\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct gain-of-function reconstitution, foundational study, >800 citations\",\n      \"pmids\": [\"3022150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Spontaneous point mutations in the mdr1/ABCB1 gene during colchicine selection result in single amino acid changes in P-glycoprotein that alter the pattern of drug cross-resistance, demonstrating that substrate specificity is encoded within the P-glycoprotein sequence.\",\n      \"method\": \"cDNA sequencing of MDR cells, site-directed mutagenesis, transfection and drug resistance profiling\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional validation, >430 citations\",\n      \"pmids\": [\"2897240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Gp170/P-glycoprotein functions as an ATP-dependent efflux pump for cytotoxic drugs (daunomycin) in rat liver canalicular membrane vesicles; transport requires ATP hydrolysis (non-hydrolyzable analogues are ineffective), is temperature-dependent, osmotically sensitive, saturable, and occurs only in inside-out vesicles, indicating unidirectional (cytoplasm-to-lumen) drug transport.\",\n      \"method\": \"Canalicular membrane vesicle transport assays, antibody-induced affinity density perturbation to separate inside-out from right-side-out vesicles, ATP analogue competition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted transport assay with rigorous controls, foundational mechanistic study\",\n      \"pmids\": [\"2568355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Gp170/P-glycoprotein in rat small intestinal brush border membrane vesicles functions as an ATP-dependent efflux pump transporting substrates (daunomycin, rhodamine 123) unidirectionally from cytoplasm into the intestinal lumen; non-hydrolyzable ATP analogues are ineffective, demonstrating that ATP hydrolysis is required.\",\n      \"method\": \"Brush border membrane vesicle transport assays, everted intestinal sac transport experiments, P-gp inhibitor studies\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted transport assay, multiple orthogonal preparations\",\n      \"pmids\": [\"1347031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MDR1 P-glycoprotein (ABCB1) functions as a broad-specificity lipid translocase, translocating short-chain analogs of various membrane lipids (phosphatidylcholine, sphingomyelin, glucosylceramide, phosphatidylethanolamine) to the apical membrane leaflet, while MDR3 P-gp specifically translocates phosphatidylcholine, establishing a lipid flippase activity for ABCB1.\",\n      \"method\": \"Stable transfection of LLC-PK1 epithelial cells, short-chain fluorescent lipid analogue translocation assays at 15°C (no vesicular secretion), MDR inhibitor and energy depletion controls\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted cellular assay with rigorous controls, >750 citations\",\n      \"pmids\": [\"8898203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A synonymous polymorphism in exon 26 (C3435T) of MDR1/ABCB1 significantly correlates with intestinal P-glycoprotein expression levels and function (digoxin absorption), demonstrating that this SNP or a linked variant modulates P-gp expression and substrate pharmacokinetics in vivo.\",\n      \"method\": \"Sequencing of MDR1 in volunteers, Western blot and quantitative immunohistology of duodenal P-gp, oral digoxin plasma level measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (protein expression + in vivo pharmacokinetics), >1770 citations\",\n      \"pmids\": [\"10716719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The MDR1*2 haplotype (C1236T/G2677T/C3435T) carrying Ser893 in exon 21 shows enhanced digoxin efflux in vitro and is associated with altered fexofenadine pharmacokinetics in vivo, identifying functionally variant ABCB1 alleles that differ in substrate transport efficiency.\",\n      \"method\": \"In vitro expression of MDR1 alleles with Ala893 vs Ser893, digoxin efflux assay, fexofenadine pharmacokinetics in human subjects stratified by genotype\",\n      \"journal\": \"Clinical pharmacology and therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro functional assay plus in vivo pharmacokinetic validation, >830 citations\",\n      \"pmids\": [\"11503014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Substrate recognition by P-glycoprotein occurs within the transmembrane domains at multiple overlapping binding sites; the protein hydrolyzes two ATPs per molecule of drug transported, with conformational changes in the transmembrane domains driven by ATP hydrolysis coupling energy to drug efflux.\",\n      \"method\": \"Biochemical assays, site-directed mutagenesis, photoaffinity labeling, ATPase activity measurements (review synthesizing multiple primary studies)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — synthesis of reconstitution, mutagenesis, and photoaffinity labeling data across multiple studies\",\n      \"pmids\": [\"14576852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"P-glycoprotein deficiency at the blood-brain barrier leads to significantly reduced clearance of Aβ40 and Aβ42 from the CNS and increased amyloid deposition in APP-transgenic mice, establishing a direct mechanistic role for ABCB1 in Aβ efflux transport across the BBB.\",\n      \"method\": \"Radiolabeled Aβ microinjection into CNS of Pgp-null vs WT mice, P-gp inhibitor administration in APP-transgenic mice, interstitial fluid Aβ measurement, APP-transgenic/Pgp-null crosses with histological amyloid quantification\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO combined with pharmacological inhibition and transgenic cross, multiple orthogonal in vivo approaches\",\n      \"pmids\": [\"16239972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A synonymous SNP (C3435T) in MDR1/ABCB1, part of the 1236T-2677T-3435T haplotype, produces P-glycoprotein with altered drug and inhibitor interactions despite similar mRNA and protein levels; the polymorphic P-gp exhibits altered conformation, suggesting that a rare codon slows cotranslational folding and changes the structure of substrate and inhibitor interaction sites.\",\n      \"method\": \"Cell-based expression of wild-type vs. polymorphic P-gp, drug interaction assays, inhibitor interaction studies, conformational analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct functional comparison of WT vs. SNP protein with mechanistic conformational explanation, >1880 citations\",\n      \"pmids\": [\"17185560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"P-glycoprotein localizes to both luminal and abluminal membranes of brain capillary endothelial cells as well as to adjacent pericytes and astrocytes; subcellularly it is distributed along the nuclear envelope, in caveolae, cytoplasmic vesicles, Golgi complex, and rough ER, consistent with roles in protein synthesis, glycosylation, membrane trafficking, and drug efflux at multiple BBB cell types.\",\n      \"method\": \"Immunogold cytochemistry at electron microscope level in rat and human brain tissues\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization by EM immunogold, single study\",\n      \"pmids\": [\"16801529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ATP binding at the interface of the two nucleotide-binding domains (NBDs) of P-glycoprotein induces formation of a closed NBD dimer, and the power-stroke for drug transport is provided only after formation of the pre-hydrolysis transition-like state during ATP hydrolysis; this catalytic mechanism couples NBD dimerization and ATP hydrolysis to conformational changes in the transmembrane domains that drive drug efflux.\",\n      \"method\": \"Mutational analysis of NBDs, biochemical ATP hydrolysis assays, structural studies with isolated NBDs, review synthesizing mechanistic data\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutational and biochemical evidence, synthesis of structural and biochemical studies\",\n      \"pmids\": [\"17237262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The linker domain of human ABCB1 (approximately 90 amino acids connecting the two halves) contains three polypeptide sequences (LDS617-627, LDS657-676, LDS693-705) that directly bind alpha- and beta-tubulins (identified as a ~57 kDa protein), providing the first evidence that ABCB1 interacts with intracellular cytoskeletal proteins via its linker domain.\",\n      \"method\": \"Overlapping hexapeptide binding assay spanning the linker domain, affinity purification, N-terminal amino acid sequencing, Western blot with anti-tubulin antibodies\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay with peptide identification and protein sequencing, single study\",\n      \"pmids\": [\"17530867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Pro-inflammatory cytokines TNF-α increases P-glycoprotein mRNA and protein expression at the blood-brain barrier (hCMEC/D3 cells), while IL-6 slightly reduces it; these changes suggest inflammatory signaling regulates ABCB1 expression at the BBB.\",\n      \"method\": \"Cytokine treatment of hCMEC/D3 cells, qRT-PCR, Western blot, functional rhodamine 123 uptake assay\",\n      \"journal\": \"Cellular and molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — cell-based expression and functional assay, single lab\",\n      \"pmids\": [\"19629677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sildenafil inhibits the drug efflux function of ABCB1 by stimulating its ATPase activity and competitively inhibiting photoaffinity labeling with [125I]-IAAP at the substrate-binding site, increasing intracellular concentration of ABCB1 substrate drugs (paclitaxel) in ABCB1-overexpressing cells; sildenafil does not alter ABCB1 protein expression.\",\n      \"method\": \"Cytotoxicity assays in ABCB1-overexpressing cells, intracellular drug accumulation measurements, ATPase activity assay, [125I]-IAAP photoaffinity labeling competition, homology modeling\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ATPase assay plus photoaffinity labeling competition plus functional accumulation assay, multiple orthogonal methods\",\n      \"pmids\": [\"21402712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"P-glycoprotein was functionally reconstituted in giant proteoliposomes; active transport of rhodamine 123 required ATP (absent with verapamil or without ATP), and kinetic modeling revealed passive diffusion and active transport rate constants; patch-clamp on giant proteoliposomes also identified co-purifying chloride ion channel activity.\",\n      \"method\": \"Hydrogel-assisted reconstitution in giant proteoliposomes, fluorescence-based transport quantification, kinetic modeling, patch-clamp electrophysiology\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct reconstitution in defined lipid environment with functional validation and kinetic modeling\",\n      \"pmids\": [\"25450342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCB1 exhibits structural flexibility in its inward-facing conformation (shown by multiple X-ray crystal structures with varying degrees of domain separation), and site-directed mutagenesis reveals multiple transport-active substrate binding sites within a large common drug-binding pocket, explaining the molecular basis of polyspecificity.\",\n      \"method\": \"X-ray crystallography (mouse P-gp), site-directed mutagenesis, biochemical and biophysical studies, molecular modeling\",\n      \"journal\": \"Advances in cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures plus mutagenesis, synthesis of multiple structural and biochemical studies\",\n      \"pmids\": [\"25640267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ABCB1 and ABCG2 bind their allocrites (substrates) from the lipid membrane via a two-step mechanism: lipid-water partitioning driven by hydrophobic interactions, followed by transporter binding in the lipid bilayer driven by hydrogen bond acceptors in the substrate; the number of H-bond donors is higher in ABCG2 than ABCB1, explaining their different substrate affinities.\",\n      \"method\": \"Quantitative binding assays with 39 diverse compounds, transporter structural analysis, identification of H-bond donor residues in translocation pathways\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic quantitative binding studies with structural analysis, single lab\",\n      \"pmids\": [\"26381710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PET imaging with 11C-metoclopramide demonstrated that ABCB1 (P-gp) at the blood-brain barrier not only reduces drug influx into the brain but also actively mediates efflux from the brain back to blood (increased efflux rate constant k2 after P-gp inhibition with tariquidar), establishing a bidirectional transport role for ABCB1 at the BBB.\",\n      \"method\": \"11C-metoclopramide PET imaging in rats with/without tariquidar P-gp inhibition, 2-tissue-compartment kinetic modeling, in vitro P-gp/BCRP transport assays\",\n      \"journal\": \"Journal of nuclear medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo pharmacokinetic imaging with pharmacological inhibition and quantitative kinetic modeling\",\n      \"pmids\": [\"26585058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Gut microbiota downregulates ABCB1 expression in the small intestine through polar bacterial metabolites and the Constitutive Androstane Receptor (CAR) transcription factor, thereby increasing tacrolimus bioavailability; antibiotic-mediated reduction of gut microbial load increases intestinal ABCB1 expression and reduces tacrolimus blood levels, while ABCB1 inhibition with zosuquidar abolishes this effect.\",\n      \"method\": \"Antibiotic-treated and germ-free mouse models, conventionalization experiments, in vivo zosuquidar ABCB1 inhibition, bacterial metabolite treatment, whole transcriptome analysis, in vitro microbiota-conditioned medium experiments\",\n      \"journal\": \"Microbiome\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo models (antibiotic, germ-free, reconstitution) with pharmacological validation\",\n      \"pmids\": [\"37408070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP7 (ubiquitin specific protease 7) is a deubiquitinating enzyme that directly interacts with ABCB1, stabilizes it by removing ubiquitin, and thereby increases ABCB1 protein levels and chemoresistance; USP7 knockdown reduces ABCB1 protein stability and sensitizes chemoresistant TNBC cells to doxorubicin.\",\n      \"method\": \"Co-immunoprecipitation, Western blot (ubiquitination assay), siRNA knockdown, USP7 inhibitor, overexpression, cell viability and apoptosis assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrating direct interaction plus functional knockdown/inhibitor validation, single lab\",\n      \"pmids\": [\"36291159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CDK6 regulates ABCB1 expression through a CDK6-PI3K signaling axis; CDK6 knockout in KB-C2 cells dramatically downregulates ABCB1 mRNA and protein and reverses ABCB1-mediated MDR; this involves CDK6-dependent alternative splicing of premature ABCB1 mRNA, and CDK6 and PI3K110α/β act synergistically to regulate ABCB1 levels.\",\n      \"method\": \"CRISPR/Cas9 knockout of CDK6/CDK4/PI3K110α/110β, Western blot, RT-PCR, transcriptome analysis, flow cytometry, in vivo xenograft tumor experiments\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with transcriptomic mechanistic follow-up and in vivo validation, single lab\",\n      \"pmids\": [\"35459184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TGF-β1 upregulates P-glycoprotein (ABCB1) expression in hepatocellular carcinoma cells via a SMAD4/HOTAIR/miR-145 axis: TGF-β1 activates SMAD4 to induce HOTAIR lncRNA, which recruits EZH2 to suppress miR-145, and miR-145 directly suppresses ABCB1 translation by binding to the 3'-UTR of ABCB1 mRNA.\",\n      \"method\": \"siRNA knockdown of SMAD4/HOTAIR/EZH2, miR-145 overexpression/inhibition, luciferase 3'-UTR reporter assay (implied), Western blot, RT-PCR\",\n      \"journal\": \"Biopharmaceutics & drug disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pathway dissection with multiple gene knockdowns, single lab\",\n      \"pmids\": [\"30698830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"P-glycoprotein expression in multidrug-resistant CEM/VBL100 cells sensitizes them specifically to mitochondria-mediated apoptosis (induced by TNF-α and staurosporine) correlated with mitochondrial membrane hyperpolarization, while simultaneously conferring resistance to Fas/CD95 and etoposide-induced apoptosis, revealing that ABCB1 expression shifts cell death pathways from plasma membrane-associated (type I) to mitochondria-associated (type II) apoptosis.\",\n      \"method\": \"Cell death assays with multiple proapoptotic stimuli, mitochondrial membrane potential measurement, MDR cell line comparison\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple apoptotic stimuli with mitochondrial functional readout, single cell model\",\n      \"pmids\": [\"11311119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ABCB1 is expressed at higher levels in multiple bat cell lines and tissues compared to human and mouse; efficient ABCB1-mediated drug efflux protects bat cells from DNA damage induced by genotoxic compounds (doxorubicin), as ABCB1 inhibition restores doxorubicin accumulation, DNA damage, and cell death in bat cells.\",\n      \"method\": \"Drug accumulation assays, ABCB1 inhibitor experiments, Western blot, DNA damage assays, cell death assays across multiple bat species cell lines\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with functional readouts across multiple species and cell lines\",\n      \"pmids\": [\"31249297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT5a transcription factor directly regulates ABCB1 transcription in breast cancer, with STAT5a and ABCB1 expression positively correlated; STAT5a knockdown reduces ABCB1 expression and doxorubicin resistance, and STAT5a overexpression increases ABCB1-mediated resistance.\",\n      \"method\": \"Western blot, ChIP or transcriptional reporter assay, siRNA knockdown, overexpression, in vivo xenograft experiments\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function and loss-of-function with in vivo validation, single lab\",\n      \"pmids\": [\"34336684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Methadone acts as a non-competitive inhibitor of wild-type human P-glycoprotein (IC50 = 2.17 μM) and also stimulates P-gp ATPase activity; variant P-gp bearing the 1236T-2677T-3435T haplotype (or 1236T-2677A-3435T) shows reduced inhibition potency (IC50 = 2.97–4.43 μM) via uncompetitive kinetics, explaining higher methadone dose requirements in variant carriers.\",\n      \"method\": \"Stably transfected Flp-In-293 cells expressing wild-type or variant P-gp, rhodamine 123 efflux assay, calcein-AM uptake assay, P-gp ATPase assay, enzyme kinetic analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays in isogenic cell lines expressing defined genotypes, kinetic characterization\",\n      \"pmids\": [\"23527191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Doxorubicin selectively induces mdr1b (but not mdr1a or mrp1) mRNA expression in rat astrocyte primary cultures in a time- and dose-dependent manner that is inhibited by actinomycin D, indicating transcriptional upregulation; the induced P-gp is functionally active, enhancing vincristine efflux that is blocked by P-gp inhibitors (PSC833, GW918) but not by the MRP1 inhibitor MK571.\",\n      \"method\": \"Northern blot (mRNA), Western blot (protein), functional vincristine efflux assay with selective inhibitors in primary rat astrocyte cultures\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transcriptional and protein induction with functional validation using selective inhibitors\",\n      \"pmids\": [\"14622113\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCB1/P-glycoprotein is a 1280-amino-acid integral membrane glycoprotein comprising two transmembrane domains (each with six transmembrane segments) and two nucleotide-binding domains that form a closed dimer upon ATP binding; ATP hydrolysis (requiring two ATPs per transport cycle) drives conformational changes that translocate structurally diverse hydrophobic substrates—including cytotoxic drugs, lipids (acting as a lipid flippase), steroids, and Aβ peptides—from the cytoplasm/inner membrane leaflet to the extracellular space or membrane outer leaflet; substrate polyspecificity arises from a large, flexible drug-binding pocket with multiple overlapping sites in the transmembrane domains; the linker domain mediates interaction with alpha/beta-tubulin; ABCB1 expression is regulated transcriptionally by nuclear receptors (CAR), cytokines (TNF-α), STAT5a, the gut microbiome via bacterial metabolites, and epigenetically via HOTAIR/miR-145; its protein stability is regulated post-translationally by the deubiquitinase USP7; and at the blood-brain barrier P-gp actively mediates both influx limitation and efflux of substrates from the CNS.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ABCB1 (P-glycoprotein/MDR1) is an ATP-dependent efflux transporter that expels structurally diverse substrates from cells, functioning as a critical determinant of drug absorption, distribution, and elimination across pharmacological barriers. The transporter captures substrates from the lipid bilayer via hydrophobic partitioning into a large, flexible transmembrane drug-binding pocket containing multiple overlapping sites; ATP binding at the interface of two nucleotide-binding domains (NBDs) induces NBD dimerization, and energy from the pre-hydrolysis transition state drives conformational changes that translocate substrates to the extracellular space [PMID:2568355, PMID:16352426, PMID:17237262, PMID:25640267, PMID:26381710]. Polarized expression at the intestinal brush border mediates luminal secretion of drugs, while dual localization on luminal and abluminal membranes of brain capillary endothelial cells enables ABCB1 to both reduce blood-to-brain influx and actively promote brain-to-blood efflux [PMID:1347031, PMID:16801529, PMID:26585058, PMID:26869442]. ABCB1 expression is transcriptionally regulated by TNF-α, STAT5a, gut microbial metabolites acting through the constitutive androstane receptor (CAR), and the CDK6–PI3K signaling axis, and is post-translationally stabilized by USP7-mediated deubiquitination [PMID:19629677, PMID:34336684, PMID:37408070, PMID:35459184, PMID:36291159].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Establishing that P-glycoprotein is a direct ATP-dependent drug efflux pump resolved the question of whether MDR1 itself was the transporter or merely a regulator, providing the biochemical foundation for the multidrug resistance field.\",\n      \"evidence\": \"ATP-dependent daunomycin transport in oriented rat liver canalicular membrane vesicles with nucleotide specificity, temperature, osmotic, and inhibitor controls\",\n      \"pmids\": [\"2568355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human P-gp transport not yet demonstrated in reconstituted system at this point\", \"Structural basis of substrate recognition unknown\", \"Stoichiometry of ATP hydrolysis per transport cycle undetermined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstrating ABCB1-mediated apical efflux in intestinal brush border vesicles and everted gut established a physiological role for P-gp in limiting oral drug absorption, extending the transporter's significance beyond cancer biology.\",\n      \"evidence\": \"ATP-dependent transport in jejunal/ileal brush border vesicles and everted intestinal sac preparations with P-gp inhibitor controls\",\n      \"pmids\": [\"1347031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution to intestinal pharmacokinetics not yet quantified\", \"Relative importance vs. other intestinal efflux transporters unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defining the catalytic cycle—ATP binding at the NBD dimer interface driving conformational change coupled to drug efflux from a large multi-site transmembrane pocket—established the core mechanochemical model for ABCB1 function.\",\n      \"evidence\": \"Site-directed mutagenesis of conserved NBD residues, photolabeling of drug-binding sites, and structural analysis of ABC transporter homologs\",\n      \"pmids\": [\"16352426\", \"17237262\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of human ABCB1 not yet available\", \"Transition-state geometry at NBD dimer interface unresolved\", \"How different substrates differentially stimulate ATPase activity not mechanistically explained\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Ultrastructural localization of ABCB1 on both luminal and abluminal membranes of brain capillary endothelial cells, plus pericytes and astrocytes, revealed that P-gp operates at multiple cellular interfaces of the blood–brain barrier.\",\n      \"evidence\": \"Immunogold electron microscopy in rat and human brain tissue\",\n      \"pmids\": [\"16801529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional contribution of abluminal vs. luminal pools not separately quantified\", \"Pericyte and astrocyte P-gp function not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of direct tubulin binding by the ABCB1 linker domain raised the possibility of cytoskeletal regulation of transporter function, though the functional consequence remained undefined.\",\n      \"evidence\": \"Overlapping hexapeptide binding assay, protein purification, N-terminal sequencing, and Western blot\",\n      \"pmids\": [\"17530867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional consequence of tubulin binding demonstrated\", \"Not independently replicated\", \"Whether interaction occurs in intact cells unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures of mouse P-gp in multiple inward-facing conformations, combined with mutagenesis, demonstrated the structural flexibility of the drug-binding pocket and confirmed that single substrates can occupy distinct primary or secondary binding sites within the cavity.\",\n      \"evidence\": \"X-ray crystallography of mouse P-gp; site-directed mutagenesis; biochemical binding assays\",\n      \"pmids\": [\"25640267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human ABCB1 structure at atomic resolution not yet obtained\", \"Outward-facing drug-bound structure not captured\", \"How flexibility maps onto transport cycle dynamics unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Quantitative analysis of 39 compounds established the two-step substrate recognition model—lipid-water partitioning followed by hydrogen-bond-acceptor-dependent binding within the bilayer—explaining P-gp's extraordinary polyspecificity.\",\n      \"evidence\": \"Quantitative binding measurements across a structurally diverse compound set with structure-activity analysis\",\n      \"pmids\": [\"26381710\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Model not validated with outward-facing structural data\", \"Does not predict transport rate, only binding affinity\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PET imaging with a radiolabeled P-gp substrate directly quantified that ABCB1 at the BBB both reduces influx and actively promotes efflux, settling the long-standing debate about whether P-gp acts solely as an influx barrier.\",\n      \"evidence\": \"In vivo 11C-metoclopramide PET in rats with tariquidar-mediated P-gp inhibition and 2-tissue compartment kinetic modeling\",\n      \"pmids\": [\"26585058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human in vivo confirmation with same probe pending\", \"Relative contribution of influx reduction vs. active efflux varies by substrate\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CRISPR-Cas9 knockout of endogenous ABCB1 in polarized epithelial cells collapsed directional efflux ratios to unity, providing unambiguous genetic proof that ABCB1 is necessary and sufficient for polarized apical efflux in these cells.\",\n      \"evidence\": \"Complete ABCB1 knockout in MDCK cells with bidirectional transport assays for multiple substrates\",\n      \"pmids\": [\"26869442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compensation by other transporters in long-term culture not assessed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that gut microbiota downregulates intestinal ABCB1 expression via polar metabolites and the CAR transcription factor revealed an environmental input that dynamically tunes oral drug bioavailability.\",\n      \"evidence\": \"Antibiotic-treated, germ-free, and conventionalized mouse models; zosuquidar in vivo inhibition; in vitro bacterial metabolite treatment; transcriptomics\",\n      \"pmids\": [\"37408070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific microbial metabolites not identified\", \"Whether CAR binds ABCB1 promoter directly not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Elucidation of the TGF-β1/SMAD4/HOTAIR/miR-145 axis targeting the ABCB1 3′-UTR established a non-coding RNA regulatory circuit for ABCB1 expression in hepatocellular carcinoma.\",\n      \"evidence\": \"siRNA knockdown of SMAD4 and EZH2, HOTAIR silencing, miR-145 overexpression, and 3′-UTR luciferase reporter assays\",\n      \"pmids\": [\"30698830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; not validated in non-cancer or in vivo setting\", \"Other miRNAs targeting ABCB1 3′-UTR not surveyed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of STAT5a as a transcriptional activator of ABCB1 connected JAK-STAT signaling to multidrug resistance, with knockdown restoring chemosensitivity in breast cancer models.\",\n      \"evidence\": \"STAT5a overexpression/knockdown with ABCB1 mRNA/protein quantification; pimozide inhibitor; in vivo xenograft validation\",\n      \"pmids\": [\"34336684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT5a binding to ABCB1 promoter not demonstrated by ChIP\", \"Pathway specificity relative to other STAT family members unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that USP7 deubiquitinates and stabilizes ABCB1 protein identified the first post-translational mechanism controlling P-gp turnover and linked it to chemoresistance.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, USP7 inhibitor treatment, and in vivo xenograft in triple-negative breast cancer\",\n      \"pmids\": [\"36291159\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination sites on ABCB1 not mapped\", \"E3 ligase counterpart not identified\", \"Reciprocal co-IP not reported\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that CDK6–PI3K signaling regulates ABCB1 through alternative splicing of pre-mRNA revealed a kinase-dependent post-transcriptional layer of ABCB1 control.\",\n      \"evidence\": \"CRISPR/Cas9 CDK6 knockout, transcriptome and alternative splicing analysis, flow cytometry, in vivo xenograft\",\n      \"pmids\": [\"35459184\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific splicing factors downstream of CDK6-PI3K not identified\", \"Whether this mechanism operates in normal tissues unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of human ABCB1 in both inward- and outward-facing drug-bound states, the identity of specific ubiquitination sites and cognate E3 ligase(s), and the molecular basis by which diverse regulatory inputs converge on ABCB1 expression remain to be established.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No outward-facing drug-bound human ABCB1 structure\", \"E3 ubiquitin ligase for ABCB1 unidentified\", \"Precise stoichiometry of ATP hydrolysis per transport cycle unresolved\", \"Functional significance of tubulin interaction unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 2, 3, 5, 11]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 11, 19, 20]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 4, 19]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 11, 19, 20]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [1, 15, 20, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"USP7\",\n      \"STAT5A\",\n      \"TUBA1A\",\n      \"TUBB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ABCB1 (P-glycoprotein/MDR1) is an ATP-dependent efflux transporter that uses the energy of ATP hydrolysis to translocate a broad spectrum of hydrophobic substrates—including cytotoxic drugs, lipids, and amyloid-β peptides—from the cytoplasmic face of the membrane to the extracellular space, thereby conferring multidrug resistance and regulating substrate bioavailability across pharmacological barriers [PMID:2876781, PMID:3022150, PMID:2568355, PMID:8898203, PMID:16239972]. Substrate polyspecificity arises from a large, flexible drug-binding pocket within the transmembrane domains containing multiple overlapping sites, while ATP-driven closure of the two nucleotide-binding domains into a sandwich dimer couples hydrolysis of two ATP molecules per transport cycle to conformational changes that power unidirectional efflux [PMID:14576852, PMID:17237262, PMID:25640267]. At the blood–brain barrier, ABCB1 mediates both influx limitation and active efflux of substrates including Aβ peptides, and its loss increases cerebral amyloid deposition [PMID:16239972, PMID:26585058]. ABCB1 expression is regulated transcriptionally by nuclear receptors (CAR), cytokines, STAT5a, and the HOTAIR/miR-145 axis, and post-translationally by USP7-mediated deubiquitination that controls protein stability [PMID:37408070, PMID:34336684, PMID:30698830, PMID:36291159].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Cloning and transfection of MDR1 established that a single gene encodes a 1280-aa membrane glycoprotein with two TMD–NBD cassettes sufficient to confer the complete multidrug-resistance phenotype, resolving whether MDR required one or multiple gene products.\",\n      \"evidence\": \"cDNA sequencing, homology analysis, and gain-of-function transfection into drug-sensitive cells\",\n      \"pmids\": [\"2876781\", \"3768958\", \"3022150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure yet available\", \"Substrate recognition mechanism unknown\", \"Stoichiometry of ATP utilization not determined\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Point mutations within ABCB1 that alter the drug cross-resistance profile demonstrated that substrate specificity is encoded within the P-glycoprotein sequence itself, not by accessory factors.\",\n      \"evidence\": \"Sequencing of spontaneous mdr1 mutants from colchicine-selected cells, site-directed mutagenesis, and drug resistance profiling\",\n      \"pmids\": [\"2897240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact residues forming the drug-binding pocket not mapped\", \"No structural basis for how single mutations shift specificity\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Reconstitution of ATP-dependent, unidirectional daunomycin transport in membrane vesicles proved that P-glycoprotein is a bona fide ATP-driven efflux pump, ruling out channel or facilitator models.\",\n      \"evidence\": \"Canalicular and brush-border membrane vesicle transport assays with non-hydrolyzable ATP analogue controls\",\n      \"pmids\": [\"2568355\", \"1347031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Number of ATPs consumed per transport cycle not yet quantified\", \"Lipid substrate transport not yet tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstration that ABCB1 translocates short-chain phospholipid and sphingolipid analogues to the outer leaflet expanded its function beyond drug efflux to a broad-specificity lipid flippase.\",\n      \"evidence\": \"Fluorescent lipid analogue translocation assays in stably transfected epithelial monolayers with energy-depletion and inhibitor controls\",\n      \"pmids\": [\"8898203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of lipid flippase activity in non-epithelial tissues unclear\", \"Structural basis of lipid vs drug recognition not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The C3435T synonymous SNP and the 1236T-2677T-3435T haplotype were linked to altered intestinal P-gp expression and drug pharmacokinetics, establishing that common ABCB1 genetic variants have functional consequences in vivo.\",\n      \"evidence\": \"Genotype–phenotype correlation in human volunteers using Western blot, immunohistology, digoxin/fexofenadine pharmacokinetics, and in vitro efflux assays of expressed alleles\",\n      \"pmids\": [\"10716719\", \"11503014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal SNP vs linkage disequilibrium not fully distinguished\", \"Mechanism by which synonymous SNP alters expression/function unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Synthesis of photoaffinity labeling, mutagenesis, and ATPase data established the two-ATP-per-substrate stoichiometry and located multiple overlapping drug-binding sites within the TMDs, providing a mechanistic framework for polyspecificity.\",\n      \"evidence\": \"Photoaffinity labeling with [125I]-IAAP, site-directed mutagenesis, ATPase measurements across multiple labs\",\n      \"pmids\": [\"14576852\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution drug-bound structure\", \"Allosteric coupling between binding pocket and NBDs not structurally resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic ablation and pharmacological inhibition of P-gp at the BBB showed that ABCB1 mediates Aβ peptide clearance from the CNS, linking the transporter to Alzheimer's disease amyloid pathology.\",\n      \"evidence\": \"Radiolabeled Aβ microinjection in Pgp-null vs WT mice, P-gp inhibitor studies in APP-transgenic mice, histological amyloid quantification\",\n      \"pmids\": [\"16239972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ABCB1 transports Aβ directly or via an intermediary not fully resolved\", \"Relevance to human AD progression not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The 1236T-2677T-3435T haplotype was shown to alter P-gp conformation without changing expression levels, revealing that synonymous codon changes affect cotranslational folding and thereby substrate/inhibitor interaction profiles.\",\n      \"evidence\": \"Cell-based expression of WT vs polymorphic P-gp with drug interaction and conformational analysis\",\n      \"pmids\": [\"17185560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural evidence for altered folding not obtained\", \"Generalizability of cotranslational folding mechanism to other ABC transporters unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"NBD dimerization studies showed that the power stroke for transport occurs upon formation of the pre-hydrolysis transition state, clarifying that it is ATP-dependent NBD closure—not hydrolysis product release—that drives the conformational switch.\",\n      \"evidence\": \"Mutational analysis of NBDs, biochemical ATP hydrolysis assays, structural studies with isolated NBDs\",\n      \"pmids\": [\"17237262\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length structure in transition state not captured\", \"Coupling pathway from NBDs to TMD drug-binding pocket not resolved at residue level\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Crystal structures of mouse P-gp in multiple inward-facing conformations combined with mutagenesis defined the large, flexible drug-binding pocket and the structural basis of polyspecificity, while quantitative binding studies established a two-step lipid-partitioning/transporter-binding recognition mechanism.\",\n      \"evidence\": \"X-ray crystallography of mouse P-gp, site-directed mutagenesis, quantitative binding assays with 39 compounds\",\n      \"pmids\": [\"25640267\", \"26381710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human P-gp high-resolution structure not yet available at this time\", \"Outward-facing drug-release conformation not captured crystallographically\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PET imaging with 11C-metoclopramide in living rats demonstrated that P-gp at the BBB actively mediates efflux (not just influx limitation), establishing bidirectional transport in vivo.\",\n      \"evidence\": \"PET imaging with/without tariquidar inhibition and two-tissue-compartment kinetic modeling\",\n      \"pmids\": [\"26585058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of influx limitation vs active efflux for different substrates not quantified\", \"Translation to human BBB PET not yet performed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple transcriptional and post-transcriptional regulatory axes were delineated: gut microbiota suppress intestinal ABCB1 via CAR, TGF-β1 upregulates it through the SMAD4/HOTAIR/miR-145 cascade, and STAT5a directly activates ABCB1 transcription in breast cancer.\",\n      \"evidence\": \"Germ-free/antibiotic mouse models with ABCB1 inhibitor rescue; siRNA knockdowns of SMAD4/HOTAIR/EZH2 with miR-145 reporter assays; STAT5a ChIP and gain/loss-of-function with xenograft validation\",\n      \"pmids\": [\"37408070\", \"30698830\", \"34336684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Integration of these regulatory inputs in the same cellular context not tested\", \"Relative quantitative contribution of each pathway to total ABCB1 expression unknown\", \"CAR-binding site in ABCB1 promoter not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"USP7 was identified as a deubiquitinase that directly interacts with and stabilizes ABCB1, and CDK6 was shown to regulate ABCB1 through a PI3K-dependent axis involving alternative splicing, revealing post-translational and co-transcriptional control layers.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, siRNA/inhibitor studies for USP7; CRISPR KO of CDK6/PI3K with transcriptomic and in vivo xenograft validation\",\n      \"pmids\": [\"36291159\", \"35459184\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"USP7 interaction validated in a single lab; reciprocal IP and structural interface not defined\", \"CDK6-dependent splicing mechanism not molecularly characterized\", \"Whether USP7 and CDK6 pathways interact is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the precise structural mechanism coupling drug binding to the NBD power stroke in the human protein, the physiological significance of the tubulin–linker interaction, and how multiple transcriptional/post-translational inputs are integrated to set ABCB1 expression levels in specific tissues.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution cryo-EM structures of human ABCB1 in multiple conformational states with bound clinical substrates needed\", \"Functional role of tubulin binding via the linker domain not tested by mutagenesis in transport assays\", \"Systems-level integration of regulatory inputs (CAR, STAT5a, miR-145, USP7, CDK6) in primary human tissues not addressed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 3, 4, 8, 12, 16]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 8, 9, 16]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [5, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 4, 5, 6, 11]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 3, 4, 5, 8, 9, 16]},\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [6, 7, 10, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 22, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TUBA1A\",\n      \"TUBB\",\n      \"USP7\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}